Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CoviCompareCV: CVnCoV Immunogenicity in Elderly vs Younger Adults
NCT04838847Phase 3Withdrawn
- Sponsor
- CureVac
- Start
- Oct 2021
- Primary completion
- Jan 2022
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
01
Overview
A Phase 3 trial of zorecimeran in coronavirus disease 2019 (COVID-19), sponsored by CureVac. Planned start Oct 2021; status: withdrawn.
02
Drugs
zorecimeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04838847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04838847.